Albumin and Platelet Loss during the Application of CytoSorb<sup>®</sup> in Critically Ill Patients: A post hoc Analysis of the Cyto-SOLVE Trial
Since a drop in albumin and platelets occurred during the use of CS, an increased substitution might be necessary. Knowledge of potential side effects is of great importance to prevent harm during the use of extracorporeal procedures. This knowledge should be considered for a reliable risk-benefit assessment in the future.
Authors
- Michael Zöller (ORCID: https://orcid.org/0000-0002-5337-6509)
- Sandra Frank (ORCID: https://orcid.org/0000-0002-1749-0339)
- Caroline Gräfe (ORCID: https://orcid.org/0000-0003-4580-5630)
- Helen Graf (ORCID: https://orcid.org/0009-0004-5185-7749)
- Christina Scharf (ORCID: https://orcid.org/0000-0002-5310-4116)
- Michael Paal (ORCID: https://orcid.org/0000-0001-8831-0238)
- Mathias Bruegel (ORCID: https://orcid.org/0000-0002-4034-5519)
- Uwe Liebchen (ORCID: https://orcid.org/0000-0002-4375-0923)
- Clara Isabell Brozat
- Diana Rebholz
Institutions
- LMU Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Blood Purification
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1159/000542009
- Citations
- 6
- Primary Topic
- Muscle and Compartmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.44